oncnursingnews2h
ASCO Recommends Abemaciclib for High-Risk HR+, HER2- Breast Cancer
A nurse practitioner discusses ASCO’s recommendations of CDK4/6 inhibitors—namely abemaciclib and ribociclib—in certain ...
oncnursingnews22h
FDA Delays Decision Dates for Sotorasib and Obeticholic Acid
The PDUFA dates have been pushed for sotorasib and obeticholic acid for metastatic colorectal cancer and primary biliary ...
oncnursingnews1d
Leuprolide, OCPs Manage Abnormal Uterine Bleeding in Stem Cell Transplant
Pharmacologic strategies may be able to prevent abnormal uterine bleeding in patients undergoing stem cell transplant.
oncnursingnews2d
Kathy Wilkinson, RN, BSN, OCN
Managing Severe Symptoms and Disease Progression in the GVHD Journey ...
oncnursingnews2d
Kathryn Wells, RN, MS, CPNP, CPON
Managing Severe Symptoms and Disease Progression in the GVHD Journey ...
oncnursingnews2d
Hyoung Jin Kang, MD, PhD
Managing Severe Symptoms and Disease Progression in the GVHD Journey ...
oncnursingnews4d
Upstage Lung Cancer
Nurses, Talk AEs, Interstitial Lung Disease, Before Treating With T-DXd ...
oncnursingnews6d
Making the Decision: Bispecifics Vs. CAR T-Cell Therapy in Myeloma
Providers should consider lifestyle preferences and other conditions/comorbidities before deciding between bispecific antibodies or CAR T-cell therapy in myeloma. Lifestyle preferences and baseline ...
oncnursingnews6d
FDA Approves Zolbetuximab Regimen for Locally Advanced, Unresectable Gastric/GEJ Adenocarcinoma
The FDA approved zolbetuximab-clzb (Vyloy) plus fluoropyrimidine- and platinum-containing chemotherapy for the treatment of patients with locally advanced unresectable or metastatic HER2-negative ...
oncnursingnews6d
High-Risk Myeloma Treatment Is Not One-Size-Fits-All
Treatment effectiveness can have different meanings to patients,” a physician assistant said when discussing therapy for high ...